miroliverELAP® for the Treatment of Acute Liver Failure: A Phase 1 Trial

Overview

About this study

The clinical trail will assess the safety of miroliverELAP for the treatment of acute liver failure without underlying chronic liver disease. miroliverELAP is an external liver assist combination product consisting of a single-use MIRO-001 bioengineered liver graft and an extracorporeal blood circuit. miroliverELAP Is intended to support the native (failed) liver for up to 48-hours of continuous treatment to allow time for liver recovery or to identify a transplantable liver.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

1. 18 years to 80 years old at the time of signing the informed consent
2. Subject must: 1. be deemed competent to consent by an independent qualified practitioner, or 2. have consent given by a Legally Authorized Representative
3. Be diagnosed with acute liver failure as defined as:
1. INR ≥ 2.5, and
2. Hepatic Encephalopathy Grade II-III (West Haven Criteria), and
3. Less than 4 weeks (28 days) of disease duration
4. Subject is not a candidate for liver transplant and will not become a candidate in the event of worsening conditions.

Exclusion Criteria:

1. Underlying chronic liver disease, including:
1. Acute-on-chronic liver disease
2. Acute alcoholic-associated hepatitis
3. Cirrhosis 2. Grade IV West Haven Encephalopathy Criteria
3. Previous liver transplant
4. Currently requires chronic hemodialysis (CRRT or other forms of continuous renal replacement are allowed).
5. Uncontrolled- documented infection, hypotension or refractory shock. This is defined as a need for a single vasopressor, or combination of vasopressors, that exceed a norepinephrine equivalent of 0.3 mcg/kg/min.
6. Liver injury due to trauma
7. Any current liver cancer
8. Currently on medications with a narrow therapeutic index
9. Platelet count < 40,000 μL
10. If the subject is intubated and has an acute lung injury
11. Experiencing a bleeding event, defined as:
1. Active gastrointestinal or other overt bleeding event, or
2. Hemoglobin drop > 3g/dL within the past 24 hours, or
3. Received ≥ 3 units of red blood cell transfusion within the past 24 hours
12. Female that is currently pregnant, planning to be pregnant, or currently breastfeeding 13. Refusal to receive blood products

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 5/22/2024. Questions regarding updates should be directed to the study team contact.

 

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Jody Olson, M.D.

Contact us for the latest status

Contact information:

Adam Miller

Miller.Adam@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20571195

Mayo Clinic Footer